Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors
May 30 2019 - 4:05PM
Business Wire
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;
TSX.V:BTI), ), a pre-clinical, research-stage
biopharmaceutical company developing its proprietary xB3 TM
platform technology for the delivery of therapeutics across the
blood-brain barrier (the “BBB”) and the treatment of central
nervous system (“CNS”) disorders in areas of high unmet
medical need, including brain cancers and neurodegenerative
diseases, today announced the appointment of Mario Saltarelli,
M.D., Ph.D., as non-executive director of the Bioasis board of
directors. Dr. Saltarelli served on Bioasis’ scientific advisory
board (SAB) since June 2018.
“I am delighted to welcome Mario as the non-executive director
of the Bioasis board. With a proven track record of building
successful pipelines and programs, he brings to our board his broad
leadership experience across multiple aspects of drug discovery and
clinical development, with a focus in diseases of the central
nervous system,” said Deborah Rathjen, Ph.D., Executive Chair and
President & Chief Executive Officer of Bioasis. “We look
forward to continuing to benefit from Mario’s expertise as we
advance our xB3 programs toward the clinic.”
Dr. Saltarelli has over 20 years of leadership experience in the
biopharmaceutical industry. Currently, he is Chief Medical Officer
(CMO) at Entrada Therapeutics, and held CMO positions at Syntimmune
and Annexon Biosciences. He previously held executive leadership
positions at Vertex, Mallinckrodt, Shire, AbbVie, and Pfizer. Prior
to entering the pharmaceutical industry, Dr. Saltarelli was an
Assistant Professor of Neurology at Emory University School of
Medicine in Atlanta. Dr. Saltarelli holds an M.D. and a
Ph.D. in neuroscience from Johns Hopkins University School of
Medicine in Baltimore and also completed his
neurology residency training at Johns Hopkins Hospital. Dr.
Saltarelli earned his B.S. in psychology from the University of
Illinois at Urbana-Champaign.
“After having had the opportunity to contribute to Bioasis this
past year as a member of the Scientific Advisory Board, I am
thrilled to continue to advance my role within a company that I
believe has strong potential to deliver therapeutics across the
blood-brain barrier for the treatment of disorders with serious
unmet medical needs,” said Dr. Saltarelli. “I look forward to
continuing to work with the Company’s management to help develop
these novel therapeutics.”
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3 TM platform, a proprietary technology for the
delivery of therapeutics across the BBB and the treatment of CNS
disorders in areas of high unmet medical need. The delivery of
therapeutics across the BBB represents the final frontier in
treating neurological disorders. Bioasis’ internal pipeline
programs are focused on treatments for orphan indications,
including certain brain cancers, and rare diseases, including
Gaucher’s Disease Type II. The Company maintains headquarters in
Guilford, Connecticut. Bioasis trades on the TSX Venture Exchange
under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.”
For more information about the Company, please visit
www.bioasis.us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190530005731/en/
Deborah Rathjendeborah@bioasis.us+1 203 533 7082
Christina TartagliaStern Investor
Relationschristina@sternir.com+1 212 362 1200
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Sep 2023 to Sep 2024